The Pseudomonas aeruginosa protease CtpA and type 3 secretion
铜绿假单胞菌蛋白酶CtpA和3型分泌
基本信息
- 批准号:8995635
- 负责人:
- 金额:$ 21.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-02-01 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute PneumoniaAffectAlanineAnimal ModelAntibiotic ResistanceAntibioticsAttenuatedBacteriaBurn injuryC-terminalCell Signaling ProcessChronicCleaved cellCommunicable DiseasesComplementComplexDataDefectDiseaseDisease OutbreaksDrug TargetingGenesHealthHospitalsHost DefenseHumanImmune systemIn VitroInfectionIntensive Care UnitsInvestigationLearningLifeLungMammalian CellMass Spectrum AnalysisMotivationMulti-Drug ResistanceOrganismPatientsPeptide HydrolasesPeriplasmic ProteinsPharmaceutical PreparationsPhenotypeProcessProtein Export PathwayProteinsProteolysisPseudomonas aeruginosaPseudomonas serine proteinaseResearchResistanceResolutionSepsisSerineStagingSystemTestingVirulenceVirulence FactorsWorkWound Infectionattenuationcell envelopecystic fibrosis patientscytotoxicitydesignenv Gene Productsin vivoinsightmouse modelmutantnew therapeutic targetnovelnovel therapeutic interventionpathogenperiplasmpreventprotein complexresearch studyresistant straintargeted treatment
项目摘要
DESCRIPTION (provided by applicant): The bacterium Pseudomonas aeruginosa is a common opportunistic human pathogen that causes life- threatening illnesses, including acute pneumonia, long-term lung colonization in most cystic fibrosis patients, and severe wound infections, especially in hospitalized patients and those with severe burns. Most P. aeruginosa infections are associated with compromised host defense and this, together with the common environmental occurrence of the organism, makes it the second most common cause of sepsis in the intensive care unit. The resolution of P. aeruginosa disease is challenging, in part because of its intrinsic resistance to antibiotics as well as occasional outbreaks of multi-drug-resistant strains in hospitals. Therefore, there is an urgent need to identify new targets for therapeutic attack. One of the most critical systems that P. aeruginosa uses to establish an infection is a complex protein export machine known as a type 3 secretion system. We have now discovered that inactivation of the uncharacterized P. aeruginosa gene PA5134/ctpA (periplasmic C- terminal processing protease) prevents normal type 3 secretion system activity, reduces the cytotoxicity of P. aeruginosa towards cultured mammalian cells, and severely attenuates it in an animal model of acute infection. However, we do not understand why. This exploratory project is founded on the central hypothesis that the cleavage of one or more cell envelope proteins by CtpA is required for normal type 3 secretion system activity. To test this hypothesis we will: (1) Identify substrates of CtpA and (2) Investigate the mechanism by which CtpA-dependent proteolysis affects type 3 secretion. This will provide critical insight into the roe of CtpA and a better understanding of how it affects Pa virulence. Such insight into the consequences of CtpA activity is very important, especially because this relatively accessible periplasmic protein could eventually be considered as an attractive target for therapeutic drugs that inactivate it.
描述(由申请方提供):铜绿假单胞菌是一种常见的人类机会致病菌,可导致危及生命的疾病,包括急性肺炎、大多数囊性纤维化患者的长期肺部定植和严重伤口感染,尤其是住院患者和严重烧伤患者。大多数铜绿假单胞菌感染与宿主防御受损有关,这与生物体的常见环境发生一起,使其成为重症监护病房中脓毒症的第二大常见原因。铜绿假单胞菌疾病的解决具有挑战性,部分原因是其对抗生素的内在耐药性以及医院中偶尔爆发的多重耐药菌株。因此,迫切需要确定新的治疗攻击靶点。铜绿假单胞菌用于建立感染的最关键系统之一是被称为3型分泌系统的复杂蛋白质输出机器。我们现在已经发现,未表征的铜绿假单胞菌基因PA 5134/ctpA(周质C-末端加工蛋白酶)的失活阻止了正常的3型分泌系统活性,降低了铜绿假单胞菌对培养的哺乳动物细胞的细胞毒性,并在急性感染的动物模型中严重减弱了它.然而,我们不明白为什么。该探索性项目建立在CtpA切割一种或多种细胞包膜蛋白是正常的3型分泌系统活性所需的中心假设上。为了验证这一假设,我们将:(1)确定CtpA的底物和(2)研究CtpA依赖性蛋白水解影响3型分泌的机制。这将提供关键的深入了解卵的CtpA和更好地了解它如何影响Pa毒力。这种对CtpA活性后果的洞察是非常重要的,特别是因为这种相对容易接近的周质蛋白最终可能被认为是治疗药物的有吸引力的靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW J. DARWIN其他文献
ANDREW J. DARWIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW J. DARWIN', 18)}}的其他基金
The roles of the Pseudomonas aeruginosa Prc/AlgO protease - Resubmission - 1
铜绿假单胞菌 Prc/AlgO 蛋白酶的作用 - 重新提交 - 1
- 批准号:
10312116 - 财政年份:2020
- 资助金额:
$ 21.19万 - 项目类别:
C-terminal proteolysis in the Pseudomonas aeruginosa cell envelope
铜绿假单胞菌细胞包膜中的 C 末端蛋白水解
- 批准号:
10319533 - 财政年份:2018
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
6717703 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8215878 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8241198 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8418767 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersina enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
8695130 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersina enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
9258378 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
7650987 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
The Psp response of Yersinia enterocolitica
小肠结肠炎耶尔森氏菌的 Psp 反应
- 批准号:
7186637 - 财政年份:2003
- 资助金额:
$ 21.19万 - 项目类别:
相似海外基金
Point-of-care infection identification system in 30 minutes - tackling acute pneumonia in emergency rooms and intensive care units
30分钟的床旁感染识别系统——应对急诊室和重症监护室的急性肺炎
- 批准号:
10076451 - 财政年份:2023
- 资助金额:
$ 21.19万 - 项目类别:
Grant for R&D














{{item.name}}会员




